Investigational drug · Phase 3
Andamertinib
Also called: PLB1004
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small-Cell Lung Cancer, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
8 still active
All registered trials
4
Any phase or sponsor naming "Andamertinib"
First trial start
2023
Jun 13, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Andamertinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small-Cell Lung Cancer
- NSCLC (Non-small Cell Lung Cancer)
- Non-Small Cell Lung Cancer
- EGFR Mutation
- Metastatic Lung Cancer
- MET Alteration
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Andamertinib" as an intervention, largest first.
- Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI FailurePivotal-lookingNot yet recruiting
Avistone Biotechnology Co., Ltd.Industry
NCT06970782 · 278 participants (planned) · Start May 15, 2025 · Primary completion Dec 31, 2027
Drug: Vebreltinib; PLB1004 and 1 more · For: Non-Small-Cell Lung Cancer
- Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.Pivotal-lookingRecruiting
Avistone Biotechnology Co., Ltd.Industry
NCT06574347 · 120 participants (planned) · Start Aug 7, 2024 · Primary completion Oct 31, 2026
Drug: Vebreltinib; Osimertinib and 1 more · For: Non-Small-Cell Lung Cancer
Sites: Guangzhou, China
Avistone Biotechnology Co., Ltd.Industry
NCT07336732 · 40 participants (planned) · Start Mar 11, 2026 · Primary completion Nov 2026
Drug: PLB1004 · For: Non-Small-Cell Lung Cancer
Sites: Guangzhou, China
- The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07780578 · 34 participants (planned) · Start Sep 30, 2026 · Primary completion Sep 30, 2028
Drug: Andamertinib; Anlotinib · For: Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Andamertinib: First Approval.
Blair HA · Drugs 2026
- Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study.
Yang JJ, Mu Y, Wang ZH, et al. · J Thorac Oncol 2026
- Pharmacokinetics, mass balance, and metabolism of [14C]PLB1004, a selective and irreversible EGFR-TKI in humans.
Liu D, Li Q, Yan S, et al. · Cancer Chemother Pharmacol 2025
Also in development for Non-Small-Cell Lung Cancer
- VebreltinibPLB1001Phase 36 trials
Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, Glioblastoma, Non-Small Cell Lung Cancer
- FirmonertinibAST2818Phase 34 trials
Allist Pharmaceuticals, Inc. · Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer
- CAB-AXL-ADCBA3011Phase 22 trials
BioAtla, Inc. · Non-Small-Cell Lung Cancer, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
- ImzokitugBMS-986340Phase 22 trials
Bristol Myers Squibb · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Cervical Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.